Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 123   

Articles published

JNJ 101.96 -0.15 (-0.15%)
price chart
Dispute Between Johnson & Johnson and Boston Scientific Moving to Trial
Before the deal closed, however, Guidant faced product recalls, and Johnson & Johnson renegotiated the terms of the deal, ultimately agreeing to pay $21.5 billion.
Pharmacyclics/Johnson amp; Johnson Drug Backed for EU Approval
The EU approval of Pharmacyclics (PCYC - Analyst Report) and partner Johnson & Johnson's (JNJ - Analyst Report) oncology drug Imbruvica (ibrutinib) appears well on track with the European Medicines Agency's (EMA) Committee for Medicinal Products for ...
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval  Yahoo News
Related articles »  
Johnson & Johnson's Results Boosted by Hepatitis C Drug
Sales of a new hepatitis-C drug helped boost Johnson & Johnson's second-quarter revenue by 9.1%, but executives said they don't expect the pill's sales to keep pace, and outlined several challenges facing the overall health-care market.
Johnson & Johnson Profit Jumps 13% As Hepatitis Drugs Shine  Forbes
Johnson & Johnson Earnings Good News For Gilead Sciences  Barron's (blog)
Related articles »  
Johnson & Johnson Board Approves Additional $5 Billion Stock Buyback
Sales of a new hepatitis-C drug helped boost Johnson & Johnson's second-quarter revenue by 9%, but executives said they don't expect the pill's sales to keep pace, and outlined several challenges facing the overall health-care market last week.
Why Johnson & Johnson (JNJ) Stock Is Up Today  TheStreet.com
Johnson & Johnson Announces $5 Billion Share Repurchase Program  MarketWatch
Related articles »  
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson Johnson & Johnson (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call ...
Related articles »  
Longtime BSX-J&J feud heading to trial
Johnson & Johnson and Boston Scientific have been at odds for nearly a decade, engaged in legal wrangling over a megadeal that went awry in 2004.
Related articles »  
Johnson & Johnson Earnings Should Show Pharma Business To Remain Strong
Johnson & Johnson will report its Q2 2014 earnings on July 15. We expect no significant change in the intensity of the main trends driving the company's business.
Johnson & Johnson expecting strong Q2 EPS  IG
Related articles »  
What Makes Johnson & Johnson a Healthy Dividend Investment
NEW YORK (TheStreet) -- Ever since its inception in 1886, Johnson & Johnson (JNJ) has managed to grow significantly and has been a lucrative company worthy of your investment.
Johnson & Johnson CEO: No Plans to Leave US
Johnson & Johnson's strong second-quarter earnings are thanks to the company's focus on long-term goals, particularly in the pharmaceutical business, said CEO Alex Gorsky.
Johnson & Johnson CEO: Not Relocating Overseas  ValueWalk
Related articles »  
Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May ...
Johnson & Johnson recently released its second quarter results. While the company beat consensus estimates, its stock fell slightly due to a weaker-than-expected outlook for the second half of 2014.
Related articles »